Injective technical analysis: Upward price move approaches $7.72 resistance

Injective technical analysis: Upward price move approaches $7.72 resistance
Injective jumps 7.03% today to $7.4

Injective (INJ) is trading at $7.4 after advancing 7.03% on the day. The asset remains above its key moving averages, with firm price action and notable upside momentum.

INJ price prediction
24H -0.55%
$7.2
48H -7.46%
$6.7
7D -12.57%
$6.33
1M -11.6%
$6.4
3M -66.02%
$2.46
6M -78.45%
$1.56
12M 19.61%
$8.66
Current price: $7.24 0.5 7.38%
Real-time Data 07:05
Daily range 6.84 Arrow from to Icon 7.29
Weekly range 6.56 Arrow from to Icon 8.44
Loading...

Highlights

  • Injective serves as a cross-chain Layer-1 blockchain supporting decentralized finance platforms such as exchanges, derivatives, and lending protocols.
  • Developer adoption and expanding financial services contribute to increased transactional activity and utility demand for Injective within the crypto ecosystem.
  • INJ/USD trades with sustained bullish momentum above key moving averages, with a projected range of $7.08 to $7.72 as indicators signal strong buying but overbought conditions.

Utility demand rising as DeFi infrastructure adoption broadens

Injective's status as an interoperable Layer-1 blockchain supporting a range of decentralized finance applications, including decentralized exchanges, derivatives platforms, and lending protocols, positions it as vital infrastructure within the DeFi space, according to Benzinga. The network's focus on facilitating advanced financial services encourages developer adoption and can drive broader usage, which in turn supports increased transactional activity. This underlying technological foundation continues to shape the asset's utility demand and strengthens its appeal within the broader crypto ecosystem.

Injective asset chart
Injective price dynamics. Source: TradingView.

Bullish bias persists as price nears resistance amid mixed signals

INJ/USD is trading above its MA-20 at $7.17 and MA-50 at $7.26 on the hourly chart, with additional support from the daily MA-200 at $5.49. The Ichimoku Kijun level at $7.21 marks immediate support. Momentum signals offer a mixed picture: RSI stands at 58.31, and both Bull/Bear Power and ADX favor buyers, while CCI indicates overbought conditions. MACD and Stoch RSI remain neutral, while the Awesome Oscillator continues to support the uptrend. Price action is near session highs, with a positive gap of 0.27 and elevated volatility.

Upside tilt dominates as rangebound consolidation likely

Looking ahead to the next session, projected price action is most likely to remain within the $7.08 to $7.72 band, reflecting typical volatility around current levels. There is a 67% probability of further upside, whereas downside risk is estimated at 33%. The baseline scenario envisions consolidation in this range, with a bullish extension possible if price breaks $7.72, and a reversal scenario if $7.08 fails, which would put support near $7.21 to the test.

Viktoras Karapetjanc, expert at Traders Union, sees robust upside momentum for Injective as price action remains supported by strong technical and fundamental factors. He believes the asset is well positioned within the DeFi sector, reinforced by its core role as highlighted in recent news. Current levels between $7.08 and $7.72 look stable, supported by firm moving averages and broadening demand. The outlook is constructive, with risk remaining controlled unless $7.08 is breached. "As long as Injective stays above key support and DeFi adoption continues, I expect further strength in INJ," says Karapetjanc.

Earlier, analysts noted that Injective was facing ongoing selling pressure despite positive ecosystem developments, resulting in a broadly consolidation-driven outlook. The latest technical setup shows price action building further momentum, shifting focus to an emerging upside scenario as INJ tests resistance near $7.72 and sets $7.21 as the key level to monitor for support in coming sessions.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.